Related Experiment Video
Updated: May 30, 2026

Assessment of Oxidative Damage in the Primary Mouse Ocular Surface Cells/Stem Cells in Response to Ultraviolet-C (UV-C) Damage
Published on: February 15, 2020
Ocular surface damage by ophthalmic compounds
Flavio Mantelli1, Laura Tranchina, Alessandro Lambiase
1Department of Ophthalmology, Campus Bio-Medico, University of Rome, Rome, Italy.
Purpose Of Review:
To describe the changes of the ocular surface following chronic use of eye drop therapies. The possible pathogenetic mechanisms responsible for specific signs and symptoms are described and discussed.
Recent Findings:
Topical treatments for ocular diseases may trigger an inflammatory response in predisposed patients, with local activation of immune cells and ocular surface damage. The resulting clinical picture may vary substantially, from mild to severe, sharing a red eye as a hallmark presentation. Recent in-vitro, in-vivo, and clinical data suggest that these detrimental effects are not solely related to eye drop preservatives and may be caused by the medication itself, especially for patients with preexisting ocular diseases. However, no specific tests are currently available to make a clear cut diagnosis between what is caused by the disease and what is the effect of its therapy. Patients' history and clinical features remain essential to hypothesize the underlying pathogenetic mechanism.
Summary:
Topical therapies may induce ocular surface allergic reactions, dry eye-like reactions, and epithelial damage. Patients in need of chronic therapies are at higher risk of facing these detrimental effects of eye drop therapies and should be treated with unpreserved compounds.
Insights
Chronic use of eye drops can harm the ocular surface, causing allergic reactions and dry eye symptoms. Unpreserved eye drop formulations are recommended for patients requiring long-term treatment to mitigate these adverse effects.
Area of Science:
- Ophthalmology
- Immunology
- Toxicology
Background:
- Topical ocular treatments can cause ocular surface damage and inflammation.
- Adverse effects may stem from preservatives or the medication itself, particularly in patients with pre-existing ocular conditions.
- Differentiating between disease progression and treatment-induced damage is challenging.
Purpose of the Study:
- To review ocular surface changes associated with chronic eye drop therapy.
- To discuss potential pathogenetic mechanisms behind these changes.
Main Methods:
- Review of in-vitro, in-vivo, and clinical data.
- Analysis of patient history and clinical features.
Main Results:
- Topical eye drops can induce inflammatory responses, immune cell activation, and ocular surface damage.
- Clinical presentations range from mild to severe, often including red eye.
- Detrimental effects are linked to both preservatives and the active medication.
Conclusions:
- Chronic eye drop use can lead to allergic reactions, dry eye-like symptoms, and epithelial damage.
- Patients on long-term therapy are at increased risk.
- Treatment with unpreserved eye drop compounds is advised for high-risk patients.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Glaucoma: Overview
Accessory Structures of the Eye
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...

